R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors
摘要:
The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors. (c) 2007 Elsevier Ltd. All rights reserved.
[EN] THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] ISOMERE R DE COMPOSES D'ACIDES AMINES BETA EN TANT QUE DERIVES ANTAGONISTES DU RECEPTEUR DES INTEGRINES
申请人:PHARMACIA CORPRATION
公开号:WO2004060376A1
公开(公告)日:2004-07-22
The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the αV β5 integrin without significantly inhibiting the αV β6 integrin
&agr;&ngr;&bgr;3 integrin antagonists in combination with chemotherapeutic agents
申请人:——
公开号:US06372719B1
公开(公告)日:2002-04-16
The present invention is directed to compounds of the formula
and pharmaceutically acceptable salts and isomers thereof administered in combination with chemotherapeutic agents.
本发明涉及以下结构的化合物及其药用盐和异构体,与化疗药物一起给药。
Meta-azacyclic amino benzoic acid compounds and derivatives thereof
申请人:G. D. Searle & Co.
公开号:US06013651A1
公开(公告)日:2000-01-11
The present invention is directed to compounds of the formula ##STR1## and pharmaceutically acceptable salts and isomers thereof.
本发明涉及公式##STR1##的化合物及其药用可接受的盐和异构体。
Amino benzenepropanoic acid compounds and derivatives thereof
申请人:G. D. Searle & Co.
公开号:US06100423A1
公开(公告)日:2000-08-08
The present invention is directed to compounds of the formula ##STR1## where R.sup.1 is BOC or H, R is H or lower alkyl; X and Y are the same or different halo atoms selected from the group consisting of Cl, Br or I and pharmaceutically acceptable salts and isomers thereof.
[EN] META-AZACYCLIC AMINO BENZOIC ACID COMPOUNDS AND DERIVATIVES THEREOF BEING INTEGRIN ANTAGONISTS<br/>[FR] COMPOSES D'ACIDE META-AZACYCLIQUE AMINO BENZOIQUE ET DERIVES ANTAGONISTES DE L'INTEGRINE
申请人:G.D. SEARLE & CO.
公开号:WO1999044994A1
公开(公告)日:1999-09-10
(EN) The present invention is directed to compounds of formula (1) and pharmaceutically acceptable salts and isomers thereof useful as $g(a)v$g(b)3 integrin antagonists.(FR) L'invention concerne des composés représentés par la formule (1) ainsi que des sels pharmaceutiquement acceptables et des isomères de ces composés convenant comme antagonistes de la $g(a)v$g(b)3.